^
Association details:
| Biomarker: | HER-2 amplification + KRAS exon 2 wild-type |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
370P - Trastuzumab-emtansine (T-DM1) in HER2-amplified metastatic colorectal cancer patients progressing to trastuzumab-lapatinib: The HERACLES RESCUE phase II trial
Published date:
09/05/2022
Excerpt:
The HERACLES-A trial demonstrated trastuzumab and lapatinib (T+L) activity in HER2-amplified (HER2+) KRAS exon 2 wild-type metastatic colorectal cancer (mCRC)...HER2 IHC 3+/amplification was retained on solid biopsy or circulating tumor DNA, respectively, in 5/5 (1 PR, 1 SD, 3 PD) and 2/3 pts (2 PD). OR was obtained in 1/8 [OR rate = 12.5% (95% CL 0.3-52)], while 2/8 (25.0%) had stable disease, accounting for 37.5% DCR....
